Immunocompetent mouse model for tracking cancer progression

The National Cancer Institute seeks licensees or research collaborators to develop and commercialize transgenic mice having immunocompetent rat growth hormone-firefly Luciferase-enhanced green fluorescent protein.IC: NCINIH Ref. No.: E-173-2010Advantages: A more clinically relevant in vivo model of cancer progression for testing anti-cancer therapeuticsA novel pre-clinical immunodeficient mouse model that better tracks tumor development and progression.Applications: In vivo model for studying tumor progression and testing anti-cancer therapeutics using ffLuc or eGFP labeling for bioimagingUsed to screen growth-hormone stimulating drugs for treating Achondroplasia (dwarf syndrome) or as a test for illegal performance-enhancing drugsDevelopment Status: PrototypeUpdated On: Dec 20, 2017Provider Classifications: Publications: Licensing Contacts: Lead Inventor: Inventor IC: NCIInventor Lab URL: http://ccr.cancer.gov/staff/staff.asp?profileid=13697Inv Is lead: LPM Phone: [phone]LPM Email: [e-mail] Classification: Research MaterialsDTDT Description: Research MaterialsPublication Link: https://www.ncbi.nlm.nih.gov/m/pubmed/21312195/Publication Caption: PMID: 21312195Publication Title: Day CP, et al.  Collaboration Sought: YesInstitute or Center: NCICollaboration Opportunity: Licensing onlyInventor First Name: Chi-PingInventor Last Name: Day

Source: NIH OTT Licensing Opportunities - December 21, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research